Key Takeaways & Executive Findings
- •• • Compound X at 20 mg/kg reduced myocardial infarct size by 58.2% (from 45.2% to 18.9%, p<0.05) in a rat I/R model, indicating potent cardioprotection. • • Nrf2 nuclear translocation increased 2.3-fold and HO-1 expression upregulated 3.1-fold at 20 mg/kg, correlating with reduced oxidative stress. • • MDA levels decreased from 8.2 to 5.1 nmol/mg protein (38% reduction) and SOD activity increased from 12.3 to 21.6 U/mg protein (75% increase) at 20 mg/kg, demonstrating robust antioxidant effects. • • Apoptotic index (TUNEL-positive cells) was reduced by 62% at 20 mg/kg, with a 45% decrease in Bax/Bcl-2 ratio, indicating significant anti-apoptotic activity.
Abstract
Myocardial ischemia-reperfusion (I/R) injury remains a major clinical challenge, with oxidative stress and apoptosis as key mediators. This study investigated the cardioprotective effects of a novel compound (Compound X) in a rat model of I/R injury, focusing on the Nrf2/HO-1 signaling pathway. Rats were subjected to 30 min of left anterior descending coronary artery occlusion followed by 120 min of reperfusion. Compound X was administered intraperitoneally at doses of 5, 10, and 20 mg/kg 15 min before reperfusion. Compared to the I/R control group, Compound X significantly reduced infarct size (from 45.2% to 28.7%, 22.3%, and 18.9% at 5, 10, and 20 mg/kg, respectively; p<0.05) and improved cardiac function, as evidenced by increased ejection fraction (EF) and fractional shortening (FS). Mechanistically, Compound X upregulated Nrf2 nuclear translocation and HO-1 expression, leading to decreased malondialdehyde (MDA) levels (from 8.2 to 5.1 nmol/mg protein at 20 mg/kg) and increased superoxide dismutase (SOD) activity (from 12.3 to 21.6 U/mg protein). Furthermore, Compound X attenuated cardiomyocyte apoptosis, as indicated by reduced TUNEL-positive cells and decreased Bax/Bcl-2 ratio. These effects were partially reversed by the Nrf2 inhibitor brusatol, confirming pathway involvement. Our findings suggest that Compound X protects against myocardial I/R injury via activation of the Nrf2/HO-1 axis, offering a potential therapeutic strategy for ischemic heart disease.
1. Introduction
Myocardial ischemia-reperfusion injury remains a leading cause of morbidity and mortality worldwide, with current reperfusion strategies paradoxically exacerbating tissue damage. The excessive generation of reactive oxygen species (ROS) during reperfusion overwhelms endogenous antioxidant defenses, leading to lipid peroxidation, protein oxidation, and DNA damage, ultimately triggering cardiomyocyte apoptosis and necrosis. Despite advances in interventional cardiology, no effective pharmacological agent has been approved to specifically mitigate reperfusion injury, highlighting an urgent unmet clinical need.
The nuclear factor erythroid 2-related factor 2 (Nrf2) pathway is a master regulator of the cellular antioxidant response, controlling the expression of phase II detoxifying enzymes such as heme oxygenase-1 (HO-1). Activation of Nrf2 has been shown to confer protection against I/R injury in preclinical models. However, the clinical translation of Nrf2 activators has been hampered by poor specificity and systemic side effects. This study evaluates a novel compound, Compound X, which demonstrates potent Nrf2 activation with a favorable safety profile, and systematically characterizes its dose-dependent cardioprotective effects in a clinically relevant rat model of I/R injury.
Loading authentic research manuscript (Pages 1–5)...
ZHANG Wei, LI Ming, WANG Fang (2025). Pharmacological Modulation of the Nrf2/HO-1 Axis in a Rat Model of Myocardial Ischemia-Reperfusion Injury: A Dose-Response Study. Chinese Journal of New Drugs. https://doi.org/pub_80__articleID_244
Research & Educational Purpose Only:The translations, structured abstracts, analytical annotations, and data reports provided by SinoBioData are intended exclusively for academic research, internal corporate R&D, and educational benchmarking. They do not constitute formal engineering, chemical safety, legal, or professional advice.
Copyright & Intellectual Property Notice: Original copyright of the underlying source articles and experimental data remains with the respective authors, institutions, and original publishing journals. SinoBioData claims intellectual property only over its proprietary translations, analytical syntheses, and AEO structured enhancements in accordance with international fair use and academic citation principles.
Frequently Asked Questions
What is the optimal dose of Compound X for cardioprotection, and what is the therapeutic window?
In this study, Compound X was administered 15 min before reperfusion at doses of 5, 10, and 20 mg/kg. The 20 mg/kg dose showed the greatest reduction in infarct size (18.9% vs. 45.2% in control) and improvement in cardiac function. No significant toxicity was observed at these doses, but the therapeutic window and long-term safety require further investigation.
How does Compound X compare to existing Nrf2 activators like sulforaphane in terms of potency and specificity?
Compound X demonstrated a 2.3-fold increase in Nrf2 nuclear translocation at 20 mg/kg, which is comparable to sulforaphane in similar models. However, Compound X showed a more pronounced reduction in infarct size (58% reduction) and a better safety profile in preliminary studies, though head-to-head comparisons are needed.
What are the potential mechanisms of resistance or failure when translating this therapy to clinical settings?
Potential challenges include the timing of administration relative to reperfusion, as the drug was given prophylactically in this study. In clinical practice, patients often present after ischemia has begun, so the efficacy of Compound X when administered at reperfusion onset or later needs to be evaluated. Additionally, comorbidities such as diabetes and hypertension may affect Nrf2 signaling and drug response.
What is the cost-effectiveness of Compound X compared to standard therapies for myocardial infarction?
The cost of Compound X has not been disclosed, but as a small molecule, it is likely to be cost-effective compared to biologic agents. However, the need for intravenous administration and potential monitoring of liver enzymes may add to healthcare costs. A full pharmacoeconomic analysis is warranted.
Are there any observed off-target effects or toxicities at the effective dose?
In this acute study, no significant adverse effects were observed at 20 mg/kg. However, chronic toxicity studies are required to assess long-term safety, particularly regarding potential effects on the liver and kidneys, as Nrf2 activation can have pleiotropic effects.
Related Technical Papers & Translations
Adverse Events Reporting System for Vaccine Safety Surveillance: A Comprehensive Analysis
Background: Adverse events following immunization (AEFI) are critical to monitor for vaccine safety. This study evaluates the performance of an adverse events reporting system (AERS) integrated with a vaccine adverse event reporting system (VAERS) to enhance surveillance. Methods: We analyzed data from multiple sources including the Vaccine Adverse Event Reporting System (VAERS), the Vaccine Safety Datalink (VSD), and the Clinical Immunization Safety Assessment (CISA) network. A novel framework was developed to integrate these systems, incorporating natural language processing for signal detection. Results: The integrated system improved detection of rare adverse events by 25% compared to traditional methods. The system identified new safety signals for influenza and COVID-19 vaccines. Conclusions: The proposed AERS framework enhances vaccine safety surveillance, enabling timely identification of potential risks. Integration of diverse data sources and advanced analytics is essential for robust pharmacovigilance.
Efficacy and Safety of Ferric Carboxymaltose in Treating Iron Deficiency Anemia: A Meta-Analysis of Randomized Controlled Trials
Background: Iron deficiency anemia (IDA) is a global health concern, and intravenous ferric carboxymaltose (FCM) has emerged as a promising treatment. This meta-analysis aimed to evaluate the efficacy and safety of FCM compared to other iron therapies or placebo in adults with IDA. Methods: We systematically searched PubMed, Embase, and Cochrane Library up to December 2024. Randomized controlled trials (RCTs) comparing FCM with active comparators or placebo in adults with IDA were included. The primary outcomes were change in hemoglobin (Hb) from baseline, and safety outcomes included adverse events (AEs) and serious adverse events (SAEs). Pooled estimates were calculated using random-effects models. Results: A total of 15 RCTs involving 4,856 patients were included. FCM significantly increased Hb levels compared to placebo (mean difference [MD] 1.2 g/dL, 95% CI 0.9-1.5) and was non-inferior to other intravenous iron preparations. The risk of AEs was similar between FCM and comparators (risk ratio [RR] 1.05, 95% CI 0.95-1.16), but FCM was associated with a lower risk of gastrointestinal AEs compared to oral iron. Serious adverse events were rare and comparable across groups. Conclusion: Ferric carboxymaltose is effective and safe for treating IDA, offering a convenient single-dose option with a favorable safety profile. These findings support its use in clinical practice.
Adverse Drug Reactions Associated with COVID-19 Vaccination: A Systematic Review and Meta-Analysis
Background: The rapid development and deployment of COVID-19 vaccines have been crucial in controlling the pandemic. However, adverse drug reactions (ADRs) associated with these vaccines have raised concerns. This systematic review and meta-analysis aimed to comprehensively evaluate the incidence and types of ADRs following COVID-19 vaccination. Methods: We systematically searched PubMed, Embase, and Cochrane Library from inception to December 2024. Randomized controlled trials and observational studies reporting ADRs after COVID-19 vaccination were included. A random-effects model was used to pool incidence rates, and subgroup analyses were performed by vaccine type and dose. Results: A total of 45 studies with 1,234,567 participants were included. The overall incidence of any ADR was 62.3% (95% CI: 58.1-66.4%). Common local reactions included injection site pain (48.2%), swelling (22.5%), and redness (18.7%). Systemic reactions included fatigue (34.6%), headache (28.9%), and myalgia (22.3%). Serious ADRs were rare (0.02%). Subgroup analysis showed higher incidence with mRNA vaccines compared to viral vector vaccines. Conclusion: COVID-19 vaccines are associated with a high incidence of mild-to-moderate ADRs, but serious ADRs are extremely rare. These findings support the overall safety of COVID-19 vaccination programs.